Blog - Page 2437 of 5623

ThursdayDec 15, 2016 10:12 am

Hope for HIV Patients as Cytodyn Inc. (CYDY) Therapy Proves Efficacy during Clinical Trials

PRO 140, an innovative new therapy for HIV patients developed by Cytodyn Inc. (OTCQB: CYDY), is currently undergoing phase 3 clinical trials, having been administered to several patients, according to a company press release (http://dtn.fm/F40vr). No other details were provided about the initial results of phase 3 trials, but a separate report said actor Charlie Sheen is one of the subjects and that he has achieved undetectable viral load after taking PRO 140. Sheen, who revealed his HIV status in November last year, has been a part of the study for eight months and is receiving weekly injections of the…

WednesdayDec 14, 2016 2:11 pm

Singlepoint, Inc. (SING) Maintaining a Positive Outlook on the Future of Marijuana Sales Processing

Despite California still looking to Trump to address marijuana industry banking challenges, Singlepoint, Inc. (OTC: SING) is maintaining a positive outlook on the future of marijuana sales processing in the state. An article by Above the Law (http://dtn.fm/p18Am) suggests that California may be able to secure bank accounts relating to cannabis businesses as long as the FinCEN cannabis banking guidelines from 2014 hold up and certain enterprising financial institutions become more willing to experiment. As a result of the passing of Proposition 64, many are confident that some of California’s financial institutions will be taking advantage of FinCEN’s 2014 guidelines…

WednesdayDec 14, 2016 12:37 pm

Monaker Group, Inc. (MKGI) Making Travel Planning Easier Through Its Flagship NextTrip.com

According to 4Hoteliers (http://dtn.fm/zOeA9), 85% of travelers across the world are also smartphone users. The article goes on to state that 32% of these travelers use their mobile devices to book travel-related services. The company’s recent webinar, ‘Digital Marketing and Mobile Trends Impacting the Travel Industry’, showed that over 70% of travelers use mobile devices to check their itineraries. But the increase in mobile usage for travel is not all that is impacting the industry. A more experience-based economy, the new social ecosystem we live in, and the growing preference for recommendations from peers are just some of the digital…

WednesdayDec 14, 2016 10:10 am

eXp World Holdings, Inc. (EXPI) Maintaining a Positive Outlook for the Real Estate Industry in the U.S.

eXp World Holdings, Inc. (OTCQB: EXPI), the holding company for the agent-owned cloud-brokerage eXp Realty LLC, is maintaining a positive attitude toward the coming year. Most recently, RISMedia (http://dtn.fm/6JKt6) published a study highlighting the fact that more real estate executives are confident about their own local economies than about the world economy. Yet many real estate executives are concerned about risks posed by rising costs for traditional real estate, especially if the market should slump. eXp World Holdings, Inc. is of the same opinion, pointing out that expenditures on brick and mortar facilities would remain fixed in the face of…

TuesdayDec 13, 2016 10:13 am

eXp World Holdings, Inc. (EXPI) Announces eXp Realty’s Reception of the Oklahoma 2016 Top Workplaces Award

In a news release issued late Monday, eXp World Holdings, Inc. (OTCQB: EXPI) announced that eXp Realty, the company’s full-service real estate brokerage, was recently recognized as one of the top workplaces in the state of Oklahoma by The Oklahoman newspaper. Based upon feedback from workplace members gathered through independent surveys by both The Oklahoman and Workplace Dynamics, the Agent-Owned Cloud Brokerage® earned the second spot in the annual list’s small-employer category, joining an impressive roster of 17 ‘Top Workplaces’ newcomers. “This is a tremendous honor for all of the agents and brokers who are on our team,” Micah Mruwat,…

FridayDec 09, 2016 1:57 pm

MediWound Ltd. (MDWD) Receives Consensus Analysts Rating of ‘Buy’

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company in the business of developing, manufacturing, and globally commercializing products that treat severe burns and wounds. In 2012, MediWound’s innovative drug, NexoBrid™, a burn and wound eschar removal agent, was approved by the European Medicines Agency (EMA) via a centralized procedure. The drug was given orphan indication for removal of dead and damaged skin in adults with burns that are deep partial and full thickness thermal burns. NexoBrid™ was launched throughout Europe and is now being used in patients with hospitalized burns and wounds. MediWound has initiated phase III clinical trials on…

FridayDec 09, 2016 10:09 am

Globus Medical, Inc. (GMED) Class A Stock Sees Significant Volume Spike Moving Into 2017

As an eventful year for Globus Medical, Inc. (NYSE: GMED) is nearing an end, the leading medical device company experienced a substantial surge in trading volume on December 06. Equities.com (http://dtn.fm/Rab1C) noted a 1.3% gain of Globus Medical, Inc. Class A stock, closing at $23.31. The stock, which averages a daily volume of 1.11 million shares over the last month, captured the attention of numerous institutional investors and analysts when a surge of 11.57 million shares traded hands on 28,116 trades. The article states, “Generally speaking, when a stock experiences a sudden spike in trading volume, it may be seen…

ThursdayDec 08, 2016 5:57 pm

New to Investing? Get Started at QualityStocks!

Investing in publicly traded companies is much easier than what it used to be. Now you can sign up for your own online trading account and be approved in just a few days. From there all you have to do is enter the symbol of the stock you wish to purchase as well as how many shares you want. With so much competition in the online brokerage market today, many are offering low commission rates as well as free independent research tools to make better trading decisions. Our name emphasizes the commitment we have to connect subscribers with companies that…

ThursdayDec 08, 2016 5:29 pm

Intellipharmaceutics International, Inc. (IPCI) Receives Aegis Update

Intellipharmaceutics International, Inc. (NASDAQ: IPCI) is a pharmaceutical company in the business of researching, developing, and manufacturing new and generic controlled and targeted release oral solid dosage drugs. The company has a large product portfolio which all follow a New Drug Application (NDA) 505(b)(2) U.S. Food and Drug Administration (FDA) regulatory pathway. The company’s controlled-release generic products follow an Abbreviated New Drug Application (ANDA) pathway. IPCI currently has 11 products in the pipeline, more than half of which have either been filed for FDA approval or have already been approved. Two products, Regabatin™ XR and Carvedilol, are still in clinical…

ThursdayDec 08, 2016 4:28 pm

Revance Therapeutics, Inc. (RVNC) is “One to Watch”

Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company focused on the development, commercialization, and manufacture of botulinum toxin products for use in aesthetic and therapeutic indications, including dermatology and neurology, recently announced its operating results for the third quarter of 2016 ended September 30. A summary of the company’s financial results highlighted research and development expenses of $10.3 million for the three-month period, $2.7 million less than in the same quarter of 2015. The decrease in expenses was largely attributable to a reduction in clinical trial activities. Research and development costs for the nine-month period were up $5.3 million. The…

Site Search

Company Search